{"id":"fc704132-fac5-50e4-ae1e-9ef41510dcf4","stable_key":"e69ef6a0-0e23-5eac-aca1-cf333781b962:ino-scyllo-biomarker","predicate":"decreases","statement":"The 250-mg twice-daily scyllo-inositol group had reduced CSF amyloid-beta x-42 despite no significant clinical benefit.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"14cb9768-ba8f-5853-918a-c9678c79fc09","mechanism_event_label":"A biomarker moved without demonstrated improvement in how patients functioned.","subject":{"id":"da2f3c6c-26e6-5337-a9a2-9f5e55931496","slug":"scyllo-inositol","display_name":"Scyllo-inositol","entity_type_key":"small_molecule"},"object":{"id":"912a2268-bc6e-5e7e-901f-14b0cf2b5df6","slug":"csf-amyloid-beta-42","display_name":"CSF amyloid-beta x-42 concentration","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"14cb9768-ba8f-5853-918a-c9678c79fc09","stable_key":"e69ef6a0-0e23-5eac-aca1-cf333781b962:ino-scyllo-biomarker-event","event_type":"observed_intervention","label":"A biomarker moved without demonstrated improvement in how patients functioned.","description":"The 250-mg twice-daily scyllo-inositol group had reduced CSF amyloid-beta x-42 despite no significant clinical benefit.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"da2f3c6c-26e6-5337-a9a2-9f5e55931496","slug":"scyllo-inositol","display_name":"Scyllo-inositol","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"912a2268-bc6e-5e7e-901f-14b0cf2b5df6","slug":"csf-amyloid-beta-42","display_name":"CSF amyloid-beta x-42 concentration","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/inositol-research/21917766.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"12c45a11b8cd0ee3075caa1f7572feae2130af237934a0be5f388322b64a1040\", \"start_char\": 0, \"end_char\": 1479, \"text_sha256\": \"12c45a11b8cd0ee3075caa1f7572feae2130af237934a0be5f388322b64a1040\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomized dose-ranging phase 2 trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Scyllo-inositol (ELND005) 250, 1000 or 2000 mg twice daily versus placebo for up to 78 weeks","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Distinct stereoisomer from myo-inositol. Higher-dose arms stopped for safety imbalance; biomarker changes do not establish clinical benefit.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Inositol research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"inositol","display_name":"Inositol (stereoisomer family)","entity_type_key":"chemical_species"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"A biomarker moved without demonstrated improvement in how patients functioned.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[ino-p21917766] A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. (2011). https://pubmed.ncbi.nlm.nih.gov/21917766/ DOI: 10.1212/wnl.0b013e3182309fa5","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"353 participants with mild-to-moderate Alzheimer disease","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"541dd34a-37cd-5772-b167-93527e3703fe","evidence_kind":"source_excerpt","locator":"Lines 1484-1495","start_line":1484,"end_line":1495,"excerpt":"### ino-scyllo-biomarker\nThe 250-mg twice-daily scyllo-inositol group had reduced CSF amyloid-beta x-42 despite no significant clinical benefit.\nCondition category: normal\nnutrient_topic: Inositol research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: A biomarker moved without demonstrated improvement in how patients functioned.\norganism: Homo sapiens\ntissue_or_cell_type: 353 participants with mild-to-moderate Alzheimer disease\nexperimental_model: Randomized dose-ranging phase 2 trial\nlimitations: Distinct stereoisomer from myo-inositol. Higher-dose arms stopped for safety imbalance; biomarker changes do not establish clinical benefit.\nexposure: Scyllo-inositol (ELND005) 250, 1000 or 2000 mg twice daily versus placebo for up to 78 weeks\nevidence_span: {\"source_cache\": \"artifacts/inositol-research/21917766.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"12c45a11b8cd0ee3075caa1f7572feae2130af237934a0be5f388322b64a1040\", \"start_char\": 0, \"end_char\": 1479, \"text_sha256\": \"12c45a11b8cd0ee3075caa1f7572feae2130af237934a0be5f388322b64a1040\"}\n[ino-p21917766] A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. (2011). https://pubmed.ncbi.nlm.nih.gov/21917766/ DOI: 10.1212/wnl.0b013e3182309fa5","model_system":"Randomized dose-ranging phase 2 trial","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [ino-p21917766] A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. (2011). https://pubmed.ncbi.nlm.nih.gov/21917766/ DOI: 10.1212/wnl.0b013e3182309fa5","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"d590c659-b774-50e6-9f1d-aff61d5f7c9c","stable_key":"import-e69ef6a0-0e23-5eac-aca1-cf333781b962","title":"Inositol: synthesis, signaling, mineral interactions and conditional deficiency (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"f7adbcedad647d5f8a3cc9e46bfa515e83c508be9c2a4e9d59c5f5dfb0667d53","revision_id":"a82d187c-60fb-52d1-8482-eadb92860f33","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}